Precision targeting of the plasminogen activator inhibitor-1 mechanism increases efficacy of fibrinolytic therapy in empyema.

In contrast to the treatment of chemically induced injury (Figure 2a , TCN), 2.0 mg/kg DSP adversely affected the outcome of fibrinolytic therapy with scuPA but showed a trend ( p >0.05) towards improvement with sctPA (Figure 2a , Empyema).

also in 53,322 other papers